Novartis ADR Share News

The market remains near record highs with the best-ever presidential election year return and 13th-best S&P return through the first half of the year. Free cash flow yield is the best valuation metric since 1990, averaging 17.6% annual returns for the most undervalued companies over the last 33 years. Screening for high free cash flow yield dividend aristocrats can provide a diversified portfol...

Stocks have been on fire since October lows, with many investors worried about bubbles and looming corrections. Even with the market at an all-time high, there are always extraordinary blue-chip bargains to buy. Optimal portfolio design with 11 sector Ultra SWAN blue-chip max volatility-adjusted return potential can provide good returns and lower volatility in bear markets.

Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.

Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology, according to Spherix Global Insights. Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology, according to Spherix Global Insights.

Italy's antitrust regulator said on Thursday it had launched a probe into several pharmaceutical companies, including Novartis , for having potentially restricted competition in the sale of a drug for eye conditions.

When it comes to seeking discounts, investors may do well with undervalued healthcare stocks. Primarily, that's because with this sector, you're dealing with a permanently relevant narrative.

Novartis AG (NYSE:NVS ) Investor Event at ASCO Conference Call June 2, 2024 7:00 PM ET Company Participants Parag Mahanti - Investor Relations Shreeram Aradhye - President of Global Drug Development and Chief Medical Officer Jeff Legos - Global Head of Oncology & Hematology Drug Development Reshema Kemps-Polanco - Chief Commercial Officer of U.S. Business Rodney Gillespie - International Therap...

Swiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care drugs in a late-stage study with details presented on Friday.